Merck KGaA reorganizes Healthcare management team

15 September 2015

Germany’s Merck KGaA (MRK: DE) today announced the reorganization of its Healthcare top management team as the business enters a new strategic phase aimed at accelerating future growth.

Effective September 30, Merck's largest business sector will be governed by the Healthcare Executive Committee, which will comprise four business functions and three supporting functions replacing the current Pharma Executive Committee. The new Healthcare Executive Committee will be chaired by Belén Garijo, a member of the Executive Board of Merck and chief executive of Merck Healthcare.

On the Healthcare Executive Committee, Simon Sturge will assume the newly-created role of chief operating officer overseeing all commercial regions and countries. In addition, his responsibilities will include the General Medicine franchise, which consists of products to treat cardiovascular diseases and diabetes, as well as Global Manufacturing and Supply. He will continue to oversee the Biosimilars and Allergopharma businesses, which he currently leads.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK